Benign Prostatic Hyperplasia
Uses
Other Proposed Natural Treatments
- Antioxidants
- Bixa orellana (Annatto)
- Flaxseed
- Flaxseed Oil
- Green Tea
- Maca
- Oat Straw
- Pumpkin Seeds
- Zinc
Principal Proposed Natural Treatments
Saw Palmetto
Pygeum
Nettle Root
Beta-sitosterol
Grass Pollen
Combination Treatment
Other Proposed Natural Treatments
References
1 Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2-7, 2001; Anaheim, CA.
2 Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate (Permixon®) [in Italian]. Urologia. 1983;50:1042-1048.
3 Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol. 1984;18:461-462.
4 Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomology caused by prostatic adenoma using an extract of Serenoa repens. Double-blind clinical study vs. placebo [in Italian; English abstract]. Minerva Urol Nefrol. 1985;37:87-91.
5 Boccafoschi C, Annoscia S. Comparison of Serenoa repens extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian]. Urologia. 1983;50:1257-1268.
6 Smith HR, Memon A, Smart CJ, et al. The value of Permixon® in benign prostatic hypertrophy. Br J Urol. 1986;58:36-40.
7 Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995;9:291-297.
8 Mattei FM, Capone M, Acconcia A. Serenoa repens extract in the medical treatment of benign prostatic hypertrophy [in Italian]. Urologia. 1988;55:547-552.
9 Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231-240.
10 Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a one-year randomized international study. Eur Urol. 2002;41:497-507.
16 Menchini-Fabris GF, Giorgi P, Andreini F, et al. New perspectives on the use of Pygeum Africanum in prostato-bladder pathology [in Italian; English abstract]. Arch Ital Urol Nefrol Androl. 1988;60:313-322.
17 Carani C, Salvioli V, Scuteri A, et al. Urological and sexual evaluation of treatment of benign prostatic disease using at high doses [in Italian; English abstract]. Arch Ital Urol Nefrol Androl. 1991;63:341-345.
18 Bombardelli E, Morazzoni P. Prunus africana (Hook f.) kalkm. Fitoterapia. 1997;68:205-218.
19 Bongi G. Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study [in Italian]. Minerva Urol. 1972;24:129-139.
20 Rizzo M. Terapia medica dell'adenoma della prostata: Valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo. Farmacia Terapia. 1985;2:105-110.
21 Ranno S, Minaldi G, Viscusi G, et al. Efficacy and tolerability of prostate adenoma treatment with Tadenan 50 [in Italian; English abstract]. Prog Med. 1986;42:165-169.
22 Bassi P, Artibani W, De Luca V, et al. Standardized extract of Pygeum africanum in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo [in Italian]. Minerva Urol Nefrol. 1987;39:45-50.
23 Barlet A, Albrecht J, Aubert A, et al. Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [translated from German]. Wien Klin Wochenschr. 1990;102:667-673.
24 Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate. 1993;22:43-51.
25 Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr Ther Res. 1995;56:796-817.
26 Kozai K, Miyake Y, Kohda H, et al. Inhibition of glucosyltransferase from Streptococcus mutans by oleanolic acid and ursolic acid. Caries Res. 1987;21:104-108.
27 Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol. 1997;157:2381-2387.
32 Vontobel HP, Herzog R, Rutishauser G, et al. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia [translated from German]. Urologe A. 1985;24:49-51.
33 Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia (BPH); double-blind study with stinging nettle root extract (Extractum Radicis Urticae—ERU) [translated from German]. Urologe B. 1987;27:223-226.
34 European Scientific Cooperative on Phytotherapy. Urticae radix. Exeter, UK: ESCOP; 1996-1997; Monographs on the Medicinal Uses of Plant Drugs, Fascicule 2:4.
37 Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83:976-983.
38 Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997;80:427-432.
39 Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol. 1986;12:187-189.
40 Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995;345:1529-1532.
41 Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995;345:1529-1532.
42 Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85:842-846.
43 Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997;80:427-432.
45 Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton®N. Results of a placebo-controlled double-blind study [translated from German]. Urologe [B]. 1988;28:301-306.
46 Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study. Br J Urol. 1990;66:398-404.
47 Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy-a multiple center double-blind study with Paraprost [in Japanese; English abstract]. Hinyokika Kiyo. 1990;36:495-516.
48 Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol. 1996;28:49-53.
49 Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton® N. Results of a placebo-controlled double-blind study [translated from German]. Urologe [B]. 1988;28:301-306.
50 Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study. Br J Urol. 1990;66:398-404.
51 Loschen G, Ebeling L. Inhibition of the arachidonate metabolism by an extract of rye pollen [in German; English abstract]. Arzneimittelforschung. 1991;41:162-167.
55 Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int. 2000;86:439-442.
56 Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163:1451-1456.
57 Wilt T, Ishani A, MacDonald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1:CD001044.
58 Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58:960-964.
59 Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, Saw Palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol. 2001;33:217-225.
60 McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
61 Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int. 2003;92:267-270.
62 Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia. N Engl J Med. 2006;354:557-66.
63 Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia. N Engl J Med. 2006;354:557-66
64 Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2006;5:1-11.
65 Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms: a placebo-controlled, double-blind, multicenter trial. World J Urol. 2005 Jun 1. [Epub ahead of print].
66 Melo EA, Bertero EB, Rios LA, et al. Evaluating the efficiency of a combination of pygeum africanum and stinging nettle (urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol. 2005;28:418-425.
67 Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study. Cancer Res. 2006;66:1234-1240.
68 Zegarra L, Vaisberg A, Loza C, et al. Double-blind randomized placebo-controlled study of Bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia. Int Braz J Urol. 2007;33:493-501.
69 Supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Feb 7.
70 Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008 Mar 21.
71 Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2009; CD001423.
72 Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-1351.
Revision Information
- Reviewer: EBSCO CAM Review Board
- Review Date: 07/2012 -
- Update Date: 07/25/2012 -